mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.008 |
mRNA |
Bortezomib |
gCSI |
pan-cancer |
AAC |
0.16 |
0.008 |
mRNA |
MST-312 |
CTRPv2 |
pan-cancer |
AAC |
0.093 |
0.008 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.01 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.094 |
0.01 |
mRNA |
triazolothiadiazine |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.01 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.01 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.01 |
mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
mRNA |
SCH-79797 |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |